Exchange: NYSE·Updated 10:31 PM EDT

BMY News

News
all
press releases
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
Zacks
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
Zacks
More News
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.
Zacks
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Zacks
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
Zacks
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Bristol Myers Squibb (BMY) reached $57.6 at the closing of the latest trading day, reflecting a -2.58% change compared to its last close.
Zacks
BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses
Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis.
Stocktwits
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
Zacks
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBios Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful...
Business Wire
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb (NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 (LPA1) antagonist, in...
Business Wire
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks

Advertisement|Remove ads.